Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of patidegib topical gel for basal cell nevus syndrome
NL-OMON55856Phase 3Active, not recruiting
- Sponsor
- PellePharm
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in basal cell carcinoma (BCC) and Basal cell nevus syndrome (BCNS) comparing Patidegib Topical Gel 2% with Vehicle (2 arms). Primary endpoint: Number of new basal cell carcinomas per subject by Month 12. Started May 2019; status: active, not recruiting.
02
Drugs
patidegib
03
Conditions
basal cell carcinoma (BCC)Basal cell nevus syndrome (BCNS)
Beyond the preview
Go deeper on NL-OMON55856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55856.